Back to results
US 10,537,599 B2Granted
Seneca valley virus (SVV) cellular receptor targeted oncotherapy
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLinde Miles, John Poirier, Charles Rudin
Life of this patent
Estimating the term…
Abstract
A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
Claims11
A method for treating cancer, comprising:
- determining an expression level of anthrax toxin receptor 1 (ANTXR1) in a cancerous tissue from a patient, and administering to the patient an effective amount of Seneca Valley Virus (SVV) if a normal expression level or an elevated expression level of ANTXR1 is detected in the cancerous tissue.
Dependencies are inferred from the claim text.